For example, IMMUNOSABR is a randomized phase II trial combining SBRT with the interventional immunotherapeutic drug Darleukin (L19-IL2) in patients with stage IV NSCLC [78]. The gene discussed is IL2; the disease is non-small cell lung carcinoma.